Pseudomonas aeruginosa and Staphylococcus aureus are the most common bacteria 21 that infect the respiratory tract of individuals with the genetic disease cystic fibrosis (CF); in fact, 22
phenotype of P. aeruginosa, which is associated with a chronic infection state, aids in 79 coexistence with S. aureus [13] , but this was performed on one reference isolate of S. aureus 80 from wound infection, JE2. 81
To date, the importance of S. aureus in CF remains controversial [8], as P. aeruginosa 82 has historically been recognized as the major pathogen. Perhaps for this reason, the majority of 83 studies on the pathogenesis of S. aureus in CF have focused on its interaction with P. 84 aeruginosa in the context of coinfection. While this is important, understanding the diversity of S. 85 aureus CF isolates themselves as well as their interactions with P. aeruginosa remains 86 understudied. For instance, there have been relatively few large-scale comparative whole 87 genomic sequence data analyses using S. aureus isolates from patients with CF and none that 88 have observed the corresponding interaction with P. aeruginosa [14] [15] [16] [17] [18] [19] [20] . 89 P. aeruginosa and S. aureus are formidable pathogens that are known to alter their 90 virulence phenotypes when shifting from acute to chronic CF lung infection. Substantial 91 research on P. aeruginosa has shown significant changes in virulence phenotypes after chronic 92 coinfection in the CF lung, most notably are changes in extracellular products [21] . Less is 93 known about S. aureus phenotypic adaptations during chronic infection. Chronic S. aureus 94 infection has been characterized by development of small colony variants and a mucoid 95 phenotype, when the bacteria overproduces polysaccharide, both which aid in persistence [22-96 28 ]. However, the prevalence of these phenotypic changes in a large number of S. aureus CF 97 clinical isolates is not well documented. Moreover, many S. aureus virulence factors are toxins 98 [29] , and studies investigating toxin production or function in a large number of CF clinical 99 isolates have not been performed. 100
Our results presented here deepen the current understanding of diversity across S. 101 aureus isolates infecting individuals with CF as well as their interactions with P. aeruginosa. We 102 obtained 64 clinical isolates of S. aureus from individuals with CF from both the Cystic Fibrosis 103 Biospecimen Registry (CFBR; a part of the Children's Healthcare of Atlanta and Emory and virulence genes. 126 To begin to determine the diversity of S. aureus isolates from individuals with CF, we 127 previously reported the genome sequences of 64 S. aureus isolates collected from 50 128 individuals with CF and the reference isolate JE2 (total of 65 isolates) as described in Bernardy, 129 et al 2019 [30] . S. aureus JE2, a derivative of USA300, was used throughout our study as a 130 control non-CF associated strain because its sequence and phenotypes were known [31] [32] [33] . 131
Our CF clinical isolates were obtained from patients with a wide range of ages and were from 132 two different sites (CFBR and Boston Children's Hospital, Table 1 ). We first created a phylogeny 133 to indicate how similar our isolates were to one another. Fig 1 shows and only three isolates had no resistance genes. CFBR_47  CFBR515  16  yes  5  8  MRSA IV  R  R  R  S  R  R  S  S  1  t008  +  +  normal  1  6.19E-03  2.21E-01  JE2  ND  ND  ND  5  8  MRSA IV  S  R  R  S  S  R  S  S  1  t008  +  +  normal  1  1.34E-03  5.73E-01  CFBR_41  CFBR429  6  no  8  8  MRSA IV  R  R  R  S  R  R  S  S  1  t400  +  -normal  1  7.89E-04  3.52E-01  CFBR_38  CFBR314  6  no  1  8  MRSA IV  R  R  R  S  R  R  S  S  1  t008  +  +  normal  1  5.56E-06  1.03E-01  CFBR_18  CFBR120  42  yes  5  8  MRSA IV  R  R  R  R  R  R  S  S  1  t008  +  +  normal  1  4.09E-03  2.37E-01  CFBR_43  CFBR447  15  yes  5  8  MRSA IV  R  R  R  S  R  R  S  S  1  t008  +  +  normal  1  9.49E-04  2.76E-01  CFBR_44  CFBR487  6  no  97  8  MRSA IV  R  R  R  S  R  R  S  S  1  t008  +  +  overproducer  1  9.43E-04  3.75E-01  CFBR_45  CFBR487  6  no  30  8  MRSA Isolates are in the same order as represented in the phylogeny (Fig 1) . Not determined (ND), Resistant (R), Sensitive (S), clear hemolysis (+), no hemolysis (-). Polysaccharide production and Coculture group are defined in Fig 2 and Fig 3, respectively.
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The accessory gene regulatory (agr) quorum sensing system controls multiple virulence 152 factors in S. aureus and is thought to be vital in infection [36] [37] [38] . There are four known types of 153 this system based on mutations and polymorphisms in the histidine kinase and autoinducer 154 peptides [39]. Among our isolates, there were 24 agr type I, 35 type II, and 6 type III (Table 1) . 155 JE2 was known as agr type I, which was confirmed by our sequence analysis. None of our 156 isolates were agr type IV; this reflects the phylogeny of the strains and what is known about agr 157 type IV due to its main association with isolates from skin infections [40] . 158
Staphylococcus protein A (spa) is implicated in virulence and typing of this gene by 159 identifying the specific repeats in its variable repeat region has historically been used to 160 distinguish between circulating variants of S. aureus during an outbreak. Among our isolates, 161 the two most common spa types are t002 (25 isolates) and t008 (10 isolates) ( Table 1) genomes. Therefore, we checked the amino acid sequence identity with a known toxin producer 170 (JE2) in order to infer function. Only 14 isolates had 100% identity with alpha toxin, but another 171 43 had at least 99% identity. For beta toxin, 21 out of 65 isolates had 100% identity with a 172 functioning beta toxin, and 44 had at least 99% identity. We are currently investigating these 173 sequences for causative mutations for those isolates lacking hemolysis. 174 175 S. aureus CF isolates hemolyze blood and produce polysaccharide.
detecting toxin genes in S. aureus CF clinical isolates is commonly performed in epidemiology 178 studies [44] , the prevalence of toxin production in a large set of S. aureus CF clinical isolates 179 has not been performed. Therefore, in order to assess the virulence capabilities of our S. aureus 180 clinical isolates, we measured the production of hemolysins on blood agar plates. Two of the 181 most prominent hemolytic toxins are alpha and beta toxin, whose production can be tested by 182 observing clear hemolysis on rabbit and sheep blood agar plates, respectively [45, 46] . Of the 183 65 isolates tested, 44 hemolyze both rabbit and sheep blood (Rabbit + / Sheep +, Table 2) , 184 confirming alpha and beta toxin production, 10 could not hemolyze either blood agar (Rabbit -/ 185
Sheep -, Table 2 ). The remaining 11 isolates were positive for only one type of blood hemolysis 186 (Rabbit + / Sheep -or Rabbit -/ Sheep +, Table 2 ). Even though all isolates had both alpha and 187 beta toxin genes present, the activity is not apparent in some of these isolates likely due to 188 mutations elsewhere in the genome. 189 Therefore, the polysaccharide production of each strain was assessed by streaking onto Congo 196 Red Agar (CRA) plates as described previously [47, 50] . Results were interpreted by observing both color and appearance (smooth vs. rough) of colonies on plates. Genetically defined 198 isogenic mutants of MN8 served as controls [49] . We observed three different phenotypes and 199 an example of each of these is plated on CRA in Fig 2. Among the 65 isolates tested, there was 200 an even split among non-producers (20 out of 65), normal polysaccharide producers (23 out of 201 65), and overproducers (22 out of 65) (Table 1) . Overall, 45 isolates (69.2%) were capable of 202 producing polysaccharides to some degree, suggesting that this phenotype is conserved in S. 203 aureus CF clinical isolates. 204
The ica operon is known to be responsible for this phenotype, specifically a 5bp deletion 205 upstream of the icaA gene is known to confer a mucoid or overproducer phenotype [47, 49] . 206
Interestingly, none of these isolates had this deletion, indicating the presence of other mutations 207 that cause this phenotype in these isolates. 208
209

S. aureus CF isolates fall into three distinct groups based on interactions with P. 210
aeruginosa. 211
Previously, it has been shown that nonmucoid PAO1 kills S. aureus lab isolate JE2, 212 while mucoid PAO1 does not [13] . Therefore, we were curious whether this trend would be 213 maintained with CF clinical isolates of S. aureus and consequently all of our 65 S. aureus 214 isolates were assessed in a coculture assay with both nonmucoid and mucoid PAO1. While a 215 number of different techniques have been used to look at how P. aeruginosa and S. aureus 216 survive in coculture [13, 51-55], we have developed a simple, repeatable, well-controlled, 217 quantitative assay for monitoring these interactions in vitro. This coculture assay allows for 218 these bacteria to come in contact with one another on a solid surface as they might in a biofilm 219 in the lung. We are also able to grow each species by itself under the same conditions in order 220 to better understand how the bacterial survival changes when grown in coculture versus alone. 221
To determine whether or not each S. aureus isolate is killed in the presence of P. 222 aeruginosa, fold change of S. aureus grown in coculture with P. aeruginosa compared to when it grew alone in the same conditions was calculated (Fig 3) . A fold change of less than 10 -2 (or 224 >100 fold decrease in cfu/ml when grown with P. aeruginosa) was considered significantly killed 225 (Fig 3, horizontal black lines) , based on other coculture assays that measure killing [56] . This 226 definition allowed us to assign each isolate into an interaction group based on how it interacted 227 with nonmucoid PAO1 and mucoid PAO1. Group 1 isolates are those that fit with the previous 228 trend observed and are only killed by nonmucoid PAO1 (Fig 3A) . We observed a range in fold 229 changes, but each fit this same trend; the black bars designating "fold change when grown with 230 nonmucoid PAO1" are all below the killing line, while the grey bars designating "fold change 231 when grown with mucoid PAO1" are all above the killing line. Most isolates fit in this group (46 232 out of 65, Fig 3A) , including previously tested isolate JE2. Group 2 isolates were those killed by 233 both nonmucoid and mucoid PAO1 (15 out of 65, Fig 3B) where both black and grey bars are 234 below the killing line. Finally, group 3 isolates were those killed by neither PAO1 strain (4 out of 235 65, Fig 3C) where both bars are above the killing line. 236
None of the S. aureus isolates that we tested affected growth of either the nonmucoid or 237 the mucoid PAO1 strain in this assay (S1 Fig) . We also determined that the decrease in survival 238 when S. aureus is grown with P. aeruginosa is due to killing not growth inhibition. This was 239 shown by performing the same coculture assay, but instead of taking one time point at 24 hours, 240
we measured cfu/ml of S. aureus alone and with P. aeruginosa at multiple time points. We 241 observed that S. aureus grows well with P. aeruginosa until approximately 12 hours when its 242 cell numbers drop dramatically (S2 Fig), suggesting that the dramatic fold changes we see are, 243 in fact, killing and not due to growth inhibition. Finally, these S. aureus isolates did not inherently 244 have different growth patterns. As shown in S3 Fig, all S. aureus isolates when grown alone 245 grow to approximately the same cfu/ml (~10 9 ) over 24 hours in the coculture assay conditions. 246
Therefore, we conclude that the differences in survival of the various S. aureus isolates when 247 grown with P. aeruginosa are not due to inherent differences in growth. 248
Discussion 250
Phylogeny relatedness to genotypes and phenotypes 251
To understand the diversity present in this set of 64 S. aureus CF clinical isolates and 252 the reference isolate JE2 (65 total), we sought to combine our genotypic and phenotypic data as 253 well as metadata obtained from the clinical lab. Most isolates belonged to CC5 and CC8 which 254 is consistent with the most commonly acquired hospital MRSA isolates, possibly suggesting 255 nosocomial acquisition. In Table 1 , the isolates are in the order placed in the phylogeny in Fig 1.  256 Therefore, we can observe genotypes and phenotypes that appear linked based on full genome 257 sequence relatedness. As expected, clonal complexes and sequence types cluster together, as 258 well as the MRSA/MSSA phenotype, agr type, and spa type (Table 1) . 259 When comparing phylogenetic relatedness and observed phenotypes, we revealed 260 some interesting connections. While rabbit and sheep hemolysis do not seem to obey any order 261 based on relatedness, comparing the polysaccharide production phenotypes in Table 1, there  262 are more normal polysaccharide-producing isolates grouped together, followed by mostly 263 overproducers, then mostly nonproducers. This clustering of phenotypes suggests a genetic 264 association; however, we know these differences are not due to the 5bp deletion in the ica 265 operon, as discussed previously. Coinfection has a similar pattern with isolates not from 266 coinfection clustering together (Table 1 , near the top) and those from coinfection clustering 267 together (Table 1 , near the bottom). We plan to continue to use the sequencing data we 268 obtained to determine a genetic basis for these phenotypes. 269
There was one connection between phylogeny and phenotypes that was notably absent; 270 there was no observed relationship between coculture interaction group and phylogeny. As 271 seen in Table 1 , there is an instance where groups cluster together, specifically, 3 out of 4 272 Group 3 isolates cluster together. But Group 1 and 2 isolates appear well distributed throughout 273 the phylogeny. This suggests that what makes these isolates a specific coculture group is more 274 complex than originally anticipated. We are currently further investigating these sequences to 275 determine genetic factors involved in the interaction between P. aeruginosa and S. aureus. 276
277
Longitudinal isolates 278
Some of our isolates were longitudinal; they came from the same individual with CF 279 (Patient ID column, Table 1 ) and were collected over a period of time. In both Table 1 and Fig 1,  280 the longitudinal isolates cluster together on the phylogeny, suggesting that these isolates all 281 originated from one initial infecting isolate, or at least isolates that are very closely related. It is 282 also interesting, although not unexpected, to see that many of their phenotypes were similar. 283
For example, most isolates collected from the same individual had the same hemolysis abilities 284 (Table 1 , Rabbit hemolysis and Sheep hemolysis columns). However, one patient, CFBR105, 285 provided four isolates in Group 1, and two isolates in Group 2. When arranged by date of 286 collection, the Group 2 isolates were both collected later, while all having the same ST, 287 suggesting that these isolates may have evolved inside the lung to no longer defend against 288 mucoid P. aeruginosa attack. These isolates also have a range of polysaccharide production, 289 suggesting more adaptation over time. However, an alternate hypothesis is that these isolates 290 were always present in the lung growing in a population, but during collection only a single 291 colony was chosen. We are currently further investigating additional isolates collected from the 292 same individuals to help us determine the genetic factors involved in adaptation to the CF lung, 293 as well as diversity of the infecting S. aureus populations. 294 295 Hemolysis and polysaccharide production were common among our isolates 296
Toxins are an important part of S. aureus virulence, and alpha toxin especially has been 297 shown to be required for pulmonary infection in CF mice [57] . Consistent with this observation, 298 most of the S. aureus clinical isolates tested produced hemolytic toxins, determined by their 299 ability to completely hemolyze both rabbit and sheep blood. Interestingly, only 10 isolates 300 (15.4%) were unable to hemolyze either blood agar. The ubiquity of hemolytic activity in these 301 isolates supports the knowledge that S. aureus toxins are important when infecting the human 302 host [29] . 303 S. aureus polysaccharide production has been implicated to be important for chronic 304 colonization in the CF lung [47] . Qualitative phenotypic characterization of polysaccharide 305 production following plating on CRA in this study shows that consistent with this hypothesis, 306 most isolates were capable of producing polysaccharide (both normal producers and 307 overproducers). Furthermore, the fact that none of the CF isolates had the conserved 5bp 308 deletion upstream of the icaA gene known to confer a mucoid or overproducer phenotype [47, 309 49], suggests a different mechanism of polysaccharide production, which we are currently 310 investigating. Twenty isolates (30.8%) were characterized as non-producers due to their red 311 color on CRA plates. These isolates may have other mechanisms for attachment and biofilm 312 production outside of this specific polysaccharide or may benefit in some other way by not 313 adhering to surfaces. We are currently investigating the genomes of these isolates for the cause 314 of this lack of polysaccharide production. Overall, polysaccharide production was common 315 among these clinical isolates, suggesting that this behavior is important in CF lung infection. 316
317
Group 1 isolates may come from initial infection 318
While it is generally understood that P. aeruginosa kills S. aureus in vitro [9-13, 51, 58] 319 and is hypothesized to also do so in vivo, these studies were performed on a small number of 320 strains and focused on how P. aeruginosa is killing S. aureus. Our studies here allow us to 321 determine if P. aeruginosa killing S. aureus is a phenotype typical of CF isolates. Our group 322 previously showed that JE2, an isolate from wound infection, was killed by nonmucoid PAO1 but 323 survived when cocultured with mucoid PAO1, and subsequently discussed the mechanism 324 behind this conclusion [13] ; therefore, we examined if CF isolates behaved similarly. The 325 majority of our isolates (46 of 65), including JE2, were killed by nonmucoid PAO1 only and we 326 subsequently called these our Group 1 isolates. While it is not surprising that these isolates 327 behaved this way due to previously defined mechanisms in Limoli, et al. [13] , it is interesting that 328 isolates from lung infection behave the same as an isolate from a wound infection in regards to 329 interaction with P. aeruginosa. Remarkably, when looking at Group 1 isolates in Table 1, many  330 were from younger patients and were sensitive to aminoglycosides and glycopeptides. This 331 observation suggests that these isolates may be from the initial stages of infection. There is a 332 known switch in predominance of infection from S. aureus in childhood to P. aeruginosa in 333 adults with CF which aligns with our observation, because S. aureus isolates from initial 334 infection could be sensitive to nonmucoid P. aeruginosa which would allow for this switch to 335 occur. 336
337
Group 2 isolates were incapable of hemolysis, but more resistant to antibiotics 338 While most isolates were in Group 1, we recognized a set of isolates that were killed by 339 both nonmucoid and mucoid PAO1, denoted Group 2 (15 out of 65 isolates). This observed 340 phenotype was surprising to us based on how often these two bacteria are thought to coinfect 341 the CF lung. It is likely that these isolates have not come in direct contact with P. aeruginosa 342 and therefore have not had a need to develop defensive strategies. These isolates may also 343 have other mutations that increased their fitness in the CF lung that coincidentally led to them 344 being less competitive with P. aeruginosa. In line with this hypothesis, half of the isolates 345 incapable of hemolyzing either type of blood agar (Rabbit -/ Sheep -, Table 2 ) were in coculture 346 Group 2. Therefore, it is tempting to speculate that these isolates may have lost some virulence 347 phenotypes resulting in lack of hemolysis and increased susceptibility to killing by P. 348 aeruginosa. While looking at Group 2 isolates in Table 1 , we noticed that many were from older 349 patients, and were resistant to methicillin (MRSA), aminoglycosides, and glycopeptides. These 350 observations may suggest that these isolates come from chronic infection due to the increase in 351 antibiotic resistances and age of the patient from which they were collected. There is also 352 research suggesting an inverse relationship between toxin production and ability to cause 353 infections, with low-cytotoxic isolates causing more pervasive infections [59] . This data supports 354 our hypothesis that these isolates might cause chronic infection because many Group 2 isolates 355 were negative for hemolysis. As previously mentioned, some of our longitudinal isolates 356 switched to a Group 2 over time in the same patient, consistent with this data. Therefore, we 357 might be observing a S. aureus adaptation over time in the CF lung where they lose expression 358 of virulence factors, similarly to P. aeruginosa. It is interesting to consider that during CF lung 359 infection, it might be more advantageous for S. aureus to retain antibiotic resistance phenotypes 360 rather than relinquish them in favor of coexistence with P. aeruginosa, leading to a Group 2 361 interaction phenotype. 362
363
Group 3 isolates were coinfected with P. aeruginosa at time of collection 364
The most surprising group of isolates are those that were resistant to killing by both 365 nonmucoid and mucoid PAO1, denoted Group 3 (4 of 65 isolates). P. aeruginosa is a potent 366 competitor and utilizes an arsenal of extracellular products and other mechanisms to kill 367 neighboring bacteria; therefore, it is interesting that these S. aureus isolates have developed 368 defensive strategies to survive coculture in vitro. Unsurprisingly, when investigating the 369 metadata associated with these isolates, we discovered that all four of these isolates, which 370 each came from a different individual, were coinfected with P. aeruginosa at the time of 371 collection. Of the 46 Group 1 isolates, 20 (43.4%) were coinfected with P. aeruginosa at the 372 time of collection, while 7 of the 15 (46.7%) Group 2 isolates were from coinfected individuals, 373 signifying that coinfection was most important for Group 3 isolates. While much work has been 374 done to show that P. aeruginosa and S. aureus do not appear to come in direct contact during 375 an established infection in a chronic wound model [60, 61] , whether this holds true in the context 376 of CF has not been clearly shown. In CF, it is possible that during initial infection there is 377 interaction between these two microbes, but that they eventually separate and create spatial 378 structure due to their antagonistic interaction, following a well-studied ecological theory [62]. It is 379 also possible that these S. aureus isolates obtained other fitness benefits from genetic changes 380 that allow coexistence with P. aeruginosa. 381 382
Diversity of S. aureus CF isolates 383
Based on the analysis performed here, we conclude that S. aureus CF clinical isolates 384 are more diverse than we hypothesized. Not only do they vary in virulence phenotypes but also 385 in their interactions with P. aeruginosa. These variations may be due to inherent differences 386 during initial infection, or evolutionary changes in response to their environment, both that of the 387 CF lung but also of the presence of other pathogens like P. aeruginosa or other members of the 388 lung microbiome [63] . Most isolates retained virulence-associated phenotypes, namely 389 hemolytic activity and mucoid phenotype, after infecting the CF lung. The mucoid phenotype 390 may aid in adhesion and can protect S. aureus from immune cell attack, so it was not surprising 391 to find that many isolates were mucoid. Many studies had previously shown that P. aeruginosa 392 kills S. aureus in a variety of in vitro experiments. Some have also shown P. aeruginosa isolates 393 that cannot kill S. aureus, however a widespread examination of S. aureus isolates and their 394 ability to withstand P. aeruginosa attack had not been performed before this study. We are 395 excited to report the amount of diversity in this interaction and plan on further investigating the 396 genetic factors involved by utilizing various molecular techniques and the sequencing data we 397 have obtained. 398
While we have not yet identified the S. aureus mechanisms involved in the diversity of 399 interaction with P. aeruginosa, we have ruled out some specific genotypes and phenotypes. We 400 conclude that this interaction is complex and multifactorial. There were no striking phenotypes 401 or genotypes that were specific or unique for each coculture interaction group. For example, S. 402 aureus polysaccharide PNAG has been implicated in persistence [47] and we know that
